SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kirby R, Fitzpatrick JM. Improved survival prospects for patients with castration-resistant prostate cancer. BJU Int 2011; 107: 697700
  • 2
    Glina S, Rivero MA, Morales A, Morgentaler A. Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins and Clarence V. Hodges. J Sex Med 2010; 7: 6404
  • 3
    Schroder FH, Hugosson J, Roobol MJ et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 98190
  • 4
    Klotz L. Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes. Curr Opin Urol 2012; 22: 22230
  • 5
    Vickers A, Bennette C, Steineck G et al. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group Randomized Trial. Eur Urol 2012; 62: 2049
  • 6
    Goldstraw MA, Challacombe BJ, Patil K. Overcoming the challenges of robot-assisted radical prostatectomy. Prostate Cancer Prostatic Dis 2012; 15: 17
  • 7
    Coelho RF, Rocco B, Patel MB et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers. J Endourol 2010; 24: 200315
  • 8
    Ahmed H, Hindley R, Dickinson L et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012; 13: 62232
  • 9
    Challacombe B, Zakri R, Murphy D, Cahill D. High intensity focused ultrasound – early experience and 2 year results. BJU Int 2009; 104: 2004
  • 10
    Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 150212
  • 11
    Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 2425
  • 12
    Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 51621
  • 13
    De Bono JS, Oudard S, Ozguroglu M et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). J Clin Oncol 2010; 28 (Suppl.): 4508
  • 14
    de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 114754
  • 15
    de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 19952005
  • 16
    Payne H, Bahl A, Mason M, Troup J, De Bono J. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU Int 2012; [Epub ahead of print]. DOI: 10.1111/j.1464-410X.2011.10886.x
  • 17
    Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 2010; 375: 143746
  • 18
    Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 308994
  • 19
    Kantoff P, Higano C, Shore D et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 41121